SonoThera raised $125 million in a Series B to take its ultrasound-based gene therapy approach into clinical testing. The company’s non-viral platform uses microbubbles activated by ultrasound to enhance delivery of genetic payloads to target tissues, with programs aimed at Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. The financing includes participation from major pharma venture arms, with Vida Ventures leading and contributions from UCB, Bayer, Otsuka Pharmaceutical, and Johnson & Johnson. SonoThera framed the funding as support for pushing lead candidates into the clinic and scaling the platform’s development. For the field, the technology targets recurring constraints in gene delivery, including safety concerns with viral vectors and manufacturing limits associated with complex gene therapy formats. If successful in humans, microbubble-and-ultrasound delivery could offer a route to broader access for genetic medicines beyond niche indications.